Clinical Trial


Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD


Brief description

This study will evaluate the efficacy and safety of QVA149 (110/50 μg o.d.) vs tiotropium (18 µg o.d.) + salmeterol/fluticasone propionate FDC (50/500 µg b.i.d.) in patients with moderate to severe COPD

Keywords

  •   Chronic Obstructive Pulmonary Disease (COPD)

Sponsored By

Novartis Pharmaceuticals

Unique Study ID

NCT02603393

Investigators and Research Sites Near You - Found( 3 )

No Investigator Listed

Sanofi
C1181ACH, Caba, Argentina
Distance from Current Trial is 0 miles

No Investigator Listed

AstraZeneca
Caba, Argentina
Distance from Current Trial is 0 miles

No Investigator Listed

Chiesi Farmaceutici S.p.A.
Caba, Argentina
Distance from Current Trial is 0 miles
View All